Latest

Jul 17, 2026, 18:44 Arvind Krishna Rebuilt IBM Around Software. Now He Has to Make the AI Stack Outrun the Mainframe Cycle

Jul 17, 2026, 16:45 Nikhil Kamath Turned Market Access Into a Media Platform. Influence Now Needs Clearer Boundaries

Jul 17, 2026, 13:40 Lucy Guo Built Passes Around Creator Ownership. Trust Must Become the Subscription Advantage

Jul 17, 2026, 10:35 Shashank Kumar Is Rewiring Razorpay Around Payment Success. Reliability Has to Pay

Jul 16, 2026, 16:45 Ritesh Agarwal Has Taken PRISM Back to the IPO Gate. Investors Will Price the Quality of OYO's Profit

Jul 16, 2026, 15:37 Nikesh Arora Made Palo Alto Networks Cybersecurity’s Consolidator. Now He Has to Make the Stack Work as One

Jul 16, 2026, 13:40 Gukesh Dommaraju Became Chess's Youngest World Champion. Defending the Crown Is a Different Business

Jul 16, 2026, 10:35 Scott Wu Joined Devin With Windsurf. The Combined Product Must Earn a US$26 Billion Valuation

Development Finance

Sania Nishtar, Chief Executive Officer of Gavi, the Vaccine Alliance

Sania Nishtar Is Rebuilding Gavi Around a US$3 Billion Funding Gap

Gavi entered its 2026–2030 strategy with more than US$9 billion pledged but roughly US$3 billion less than requested. Sania Nishtar’s answer is a leaner, country-led operating system that must protect procurement scale and accountability.

Adar Poonawalla, Chief Executive Officer of the Serum Institute of India

Adar Poonawalla’s Malaria Vaccine Capacity Is Running Ahead of the Funding Market

Adar Poonawalla has made Serum Institute central to the malaria vaccine market, with R21 capacity and a new Oxford licence for R78C. The commercial constraint is no longer supply alone, but financed demand and durable procurement.